Effectiveness of Anti-Psychotic in GPs Setting

AstraZeneca250 enrolled

Overview

Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Schizophrenia Bipolar Disorder

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with Schizophrenia or Bipolar Disorder (currently in a manic episode)

Locations (57)

Outcomes

Primary Outcomes

to evaluate the patient's functioning, by measuring the Quality of Life. Quality of Life will be assessed by the Q-LES-Q-16 (PRO).

Secondary Outcomes

The clinical efficacy & tolerability of atypical antipsychotics as assessed by the Clinical Global Impression(CGI) & Patient Global Impression of Change(PGIC)scores.

The wellbeing of the patients taking atypical antipsychotics as assessed by the Sheehan Disability Scale(SDS)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Baudour, Belgium

Research Site

Beyne-Heysay, Belgium

Research Site

Bomal, Belgium

Research Site

Bredene, Belgium

Research Site

Brussels, Belgium

Research Site

Esen, Belgium

Research Site

Evere, Belgium

Research Site

Gingelom, Belgium

Research Site

Gouy-lez-Piéton, Belgium

Research Site

Grâce-Hollogne, Belgium

...and 47 more locations